Hussain Rumana N, Banerjee Somnath
Leicester Royal Infirmary, Leicester, UK.
Clin Ophthalmol. 2011;5:603-7. doi: 10.2147/OPTH.S17753. Epub 2011 May 15.
Densiron(®) 68 is a high-density liquid used to tamponade inferior retinal detachments. We present a case series of 12 patients treated with Densiron as an intraocular tamponade agent.
A retrospective analysis of 12 eyes in 12 patients was carried out. The primary endpoint was anatomic reattachment of the retina following removal of Densiron oil.
All patients had inferior detachments; 33% had associated proliferative vitreoretinopathy (PVR). Densiron was utilized as a primary agent in five patients (42%); the remaining patients had prior unsuccessful surgery for retinal reattachment, including pars plana vitrectomy, cryotherapy, laser, encirclement, gas (C3F8 or C2F6), or silicone oil. Eleven patients (91%) had successful reattachment of the retina at 3 months following removal of Densiron; one patient had extensive PVR, total retinal detachment, preretinal macula fibrosis, and chronic hypotony, and surgical intervention was unsuccessful. Six patients (50%) had raised intraocular pressure (IOP), resolving in the majority of cases following Densiron removal; two patients had long-term raised IOP requiring topical or surgical therapy. Of the six phakic patients, 50% developed significant cataract in the operated eye. Of those with successful retinal reattachment, visual outcome was variable, with 36% patients gaining two to four lines on Snellen, 27% remaining objectively the same, and 36% losing one to two lines.
The anatomic success rate is high (91%) in patients requiring Densiron tamponade for inferior retinal detachments with or without evidence of PVR either as a primary or secondary intervention. A common complication is raised IOP; however, this most often resolves following removal of the oil.
Densiron(®) 68是一种用于填塞视网膜下脱离的高密度液体。我们报告了一组12例使用Densiron作为眼内填塞剂治疗的病例。
对12例患者的12只眼进行回顾性分析。主要终点是取出Densiron油后视网膜的解剖复位。
所有患者均为视网膜下脱离;33%伴有增殖性玻璃体视网膜病变(PVR)。5例患者(42%)将Densiron作为主要治疗药物;其余患者此前视网膜复位手术失败,包括玻璃体切割术、冷冻疗法、激光治疗、环扎术、气体(C3F8或C2F6)或硅油填充。11例患者(91%)在取出Densiron后3个月视网膜成功复位;1例患者发生广泛PVR、全视网膜脱离、黄斑前膜纤维化和慢性低眼压,手术干预失败。6例患者(50%)出现眼压升高(IOP),大多数病例在取出Densiron后眼压恢复正常;2例患者眼压长期升高,需要局部或手术治疗。6例有晶状体眼患者中,50%术眼发生明显白内障。在视网膜成功复位的患者中,视力结果各不相同,36%的患者Snellen视力提高2至4行,27%的患者视力客观上保持不变,36%的患者视力下降1至2行。
对于需要使用Densiron填塞治疗视网膜下脱离的患者,无论是否有PVR证据,作为初次或二次干预,解剖复位成功率较高(91%)。常见并发症是眼压升高;然而,这在大多数情况下会在取出油后得到缓解。